The marketing authorisation for Raptiva has been withdrawn at the request of the marketing authorisation holder.
Raptiva : EPAR - Summary for the public (PDF/476.19 KB)
First published: 04/08/2009
Last updated: 04/08/2009
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Serono Europe Limited
|Date of issue of marketing authorisation valid throughout the European Union||
Serono Europe Ltd.
56 Marsh Wall
London E14 9TP
25/11/2008 Raptiva - EMEA/H/C/000542 - II/0026
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA (see section 5.1 - Clinical Efficacy).